Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04681131 | CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC | PHASE2 | COMPLETED | 85 | — | — | Mar 17, 2021 | Jul 9, 2025 | Sep 25, 2025 | 60 | United States, Greece +5 |
Proportion of patients who achieve a confirmed CR or PR according to RECIST v1.1
Measured by frequency and severity of adverse events as assessed by CTCAE v4.03/v5
| Arm | Type | Description |
|---|---|---|
| CAB-AXL-ADC (BA3011) | EXPERIMENTAL | CAB-AXL-ADC (BA3011) alone |
| CAB-AXL-ADC (BA3011)+PD-1 inhibitor | EXPERIMENTAL | CAB-AXL-ADC (BA3011) with PD-1 inhibitor |
| Name | Type | Description |
|---|---|---|
| CAB-AXL-ADC | BIOLOGICAL | Conditionally active biologic anti-AXL antibody drug conjugate |
| PD-1 inhibitor | BIOLOGICAL | PD-1 inhibitor |
Inclusion Criteria: * Patients must have measurable disease. * Age ≥ 18 years * Adequate renal function * Adequate liver function * Adequate hematological function * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Life expectancy of at least three months. Exclusio...